BICO Group is a life science technology company that provides lab automation solutions, software, and biomaterials to accelerate scientific discovery. The company operates through three main business segments: Life Science Solutions, Bioprinting, and Lab Automation. Its portfolio includes automated workstations, lab orchestration software, and 3D bioprinting systems designed for drug discovery, diagnostics, and tissue engineering. BICO serves leading pharma and biotech companies, as well as academic and industrial research institutions, globally. The company was founded in 2015 as CELLINK and rebranded to BICO Group in 2021. Key brands in its portfolio include Biosero, which offers the Green Button Go lab orchestration software, and other specialized instruments for cell isolation and bioprinting. BICO’s technologies enable customers to improve the predictability of clinical results, enhance the traceability of biological samples, and reduce the time required for research and development.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Medical Instruments & Supplies Homepage bico.com
Sector Healthcare IR page bico.com
Tags
lab automation, bioprinting, drug discovery, tissue engineering, lab software, biomaterials, cell isolation, diagnostics, life science research, Biosero, Green Button Go
Press page —

Metrics

Valuation  
Market cap kr 1.588B
Market cap (USD) $ 157.07M
P/E -1.89
PEG —
P/BV 1.01
P/S 1.06
P/OCF 23.22
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -46.0%
ROI -62.5%
ROIC -55.4%
Profit margin -73.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 0.01%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 5
Quality score -66.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2019
Revenue 1.497B 1.946B 2.25B 2.24B 1.257B 105.457M
Net profit -1.093B -9M -1.174B -835.7M -229.2M 581K

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2019
Share price 21.1 23 57 105.8 277.8 36.5
Price performance 12m -0.08 -0.6 -0.46 -0.62 0.18 0.55

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (SEK) 176M 577M 700M 520M 451M 377M
↳ YoY growth +227.0% +21.3% -25.7% -13.3% -16.4%
↳ 5y CAGR +16.4%
Other receivables (SEK) 10.8M 88.2M 60M 53.2M 35.4M 30.8M
Borrowings, non-current (SEK) 26.7M 1.35B 1.38B 1.42B 1.34B 200,000
Lease liabilities (SEK) 80.2M 252M 460M 536M 420M 282M
Cash and deposits (SEK) 435M 481M 925M 861M 946M 1.28B
Right-of-use assets (SEK) 80.8M 249M 442M 486M 330M 239M
Net debt (borrowings + leases - cash) (SEK) -328M 1.12B 920M 1.09B 810M -1B
Cash flow detail
Operating cash flow (SEK) — -409M -269M 178M 158M 68.4M
Purchases of property, plant and equipment (SEK) — -111M -274M -171M -44.1M -13.3M
Purchases of intangible assets (SEK) — -156M -256M -120M -41.6M -11.7M
Change in receivables (cash effect) (SEK) — 353M 189M -110M -124M 1.9M
Change in inventories (cash effect) (SEK) — 170M 162M -7.2M -92.2M -16M
Change in payables (cash effect) (SEK) — -174M -85.4M -66.1M 168M -98.7M
Income taxes paid (cash effect) (SEK) — 21.5M 30.8M 51.1M 83.1M 29.1M
Operating cash flow before change in receivables (SEK) — -762M -459M 289M 283M 66.5M
Free cash flow (OCF - PPE - intangibles) (SEK) — -676M -799M -113M 72.7M 43.4M
Income detail
Research and development expense (SEK) — — — 343M 354M 205M
Total comprehensive income (SEK) — -147M -444M -1.15B -100M -1.25B
Comprehensive income to owners (SEK) — -146M -443M -1.15B -97.2M -1.25B
Reported — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

--------------------------------------------------------------------------------------------------------------](https://bico.com/news-feed/?site=bico&id=34902)

August 4, 2026 | Scienion

Breaking Barriers II: Handling Challenging Reagents with Microdispensing Technology
-----------------------------------------------------------------------------------

June 30, 2026 | Scienion

Breaking Barriers: Handling Challenging Surfaces with Microdispensing Technology
--------------------------------------------------------------------------------

May 12, 2026 | Scienion

From URS to Validated Production: Why Most Custom Automation Projects Fail
--------------------------------------------------------------------------

May 6, 2026 | Scienion

Designing a Validation-Ready Precision Dispensing Workstation: What Regulated Industries Need To Get Right
----------------------------------------------------------------------------------------------------------

April 15, 2026 | Scienion

Meet the Experts: Thomas & Simon | From Customer Requirements to Validated Custom Systems 
------------------------------------------------------------------------------------------
 

March 18, 2026 | Scienion

Meet the Experts: Talena – Empowering Customer Success Through Teamwork
-----------------------------------------------------------------------

February 24, 2026 | Scienion

How Precision Microdispensing Accelerates Adaptyx’s Wearable Biosensor Development
----------------------------------------------------------------------------------

February 11, 2026 | Scienion

Meet the Experts: Svenja on Precision Microdispensing and Assay Development | Women in Science
----------------------------------------------------------------------------------------------

Load more

Stay updated

Get the latest first.

Subscribe and stay updated with the latest news!

Subscribe

brand-Bico_Logo_RGB_Horizontal_Neg

Copyright © 2026 BICO - All rights reserved.

Contact us!

Name

Organisation

Email

Message

Submit

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

-----------------------------------------------------------------------------------](https://bico.com/news-feed/?site=scenion&id=4093)

June 30, 2026 | Scienion

Breaking Barriers: Handling Challenging Surfaces with Microdispensing Technology
--------------------------------------------------------------------------------

May 12, 2026 | Scienion

From URS to Validated Production: Why Most Custom Automation Projects Fail
--------------------------------------------------------------------------

May 6, 2026 | Scienion

Designing a Validation-Ready Precision Dispensing Workstation: What Regulated Industries Need To Get Right
----------------------------------------------------------------------------------------------------------

April 15, 2026 | Scienion

Meet the Experts: Thomas & Simon | From Customer Requirements to Validated Custom Systems 
------------------------------------------------------------------------------------------
 

March 18, 2026 | Scienion

Meet the Experts: Talena – Empowering Customer Success Through Teamwork
-----------------------------------------------------------------------

February 24, 2026 | Scienion

How Precision Microdispensing Accelerates Adaptyx’s Wearable Biosensor Development
----------------------------------------------------------------------------------

February 11, 2026 | Scienion

Meet the Experts: Svenja on Precision Microdispensing and Assay Development | Women in Science
----------------------------------------------------------------------------------------------

Load more

Stay updated

Get the latest first.

Subscribe and stay updated with the latest news!

Subscribe

brand-Bico_Logo_RGB_Horizontal_Neg

Copyright © 2026 BICO - All rights reserved.

Contact us!

Name

Organisation

Email

Message

Submit

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Single Press release

BICO slutför integrationen av Cellenion i SCIENION och stärker plattformen för precisionsbioteknik

October 2, 2026 7:00 am

BICO Group AB (publ) meddelar idag att integrationen av Cellenion i SCIENION har slutförts. Genom sammanslagningen samlas verksamheter, teknologier och medarbetare i en gemensam organisation och under ett gemensamt varumärke.

Integrationen stödjer BICOs ambition att bygga ledande positioner inom attraktiva life science-marknader, samtidigt som den operativa effektiviteten förbättras och grunden för framtida innovation stärks. Genom att konsolidera resurser, förenkla go-to-market-modellen och fokusera investeringar på kundorienterade utvecklingsprogram bedömer BICO att SCIENION står starkare positionerat för långsiktig och hållbar tillväxt. 

Inom ramen för initiativet har BICO slutfört stängningen av verksamheter och effektiviserat organisationen kring SCIENIONs kärnkompetenser inom teknologier för precisionsdispensering. Initiativet är en del av det omstruktureringsprogram som totalt kommer att generera årliga besparingar om cirka 30 Mkr, vilket kommunicerades i delårsrapporten för det första kvartalet 2026. 

SCIENION och Cellenion har historiskt verkat utifrån en gemensam teknologisk grund, men adresserat kompletterande tillämpningar inom biokemisk precisionsdispensering och single-cell-teknologier. Som en del av integrationen, och för att förenkla och förtydliga de kundnära aktiviteterna, har Cellenion-varumärket avvecklats och dess produkter införlivats i SCIENIONs varumärkesarkitektur. Produkter som tidigare marknadsfördes under Cellenion, inklusive cellenONE, spheroONE och proteoCHIP, kommer framöver att marknadsföras under SCIENION-varumärket. 

– Vi har nu slutfört både den operativa och varumärkesmässiga integrationen av Cellenion i SCIENION, säger Anders Fogelberg, vd och koncernchef, BICO. Genom att samla våra teknologier, vår kompetens och våra team i en organisation skapar vi en mer fokuserad och effektiv verksamhet samtidigt som vi stärker vår förmåga att stödja forskare, innovativa bioteknikföretag och läkemedelsbolag världen över. 

Under det gemensamma SCIENION-varumärket får kunder nu tillgång till ett bredare erbjudande inom biokemisk precisionsdispensering, isolering och dispensering av enskilda celler samt sortering av 3D-cellmodeller. Tillsammans stärker dessa teknologier SCIENIONs position som innovationspartner till forskare och life science-organisationer som söker ökad precision, effektivitet och skalbarhet i biologisk forskning och utveckling. 

Prompts

BICO Group (ticker BICO), listed in Sweden.

ETFs Holding BICO Group

ETF Weight in ETF Shares Market value As of
AVDV 0.01% 668,131 $ 1.024M Nov 16, 2026
AVDS 0.01% 12,575 $ 19.278K Nov 16, 2026
DISV 0.00% 15,114 $ 25.124K Nov 12, 2026
DFAX 0.00% 5,705 $ 9,483.26 Nov 12, 2026
DFAI 0.00% 5,367 $ 8,921.41 Nov 12, 2026
AVDE 0.00% 17,241 $ 26.432K Nov 16, 2026
AVSD 0.00% 8,339 $ 12.784K Nov 16, 2026